Trending Alert: 4 HealthTech Tickers Trending Now

Names Inside If you cannot see this email properly, please click [here]( Powered by [HealthTechMovers.com]( Dear Reader, Below is a a list of 4 Healthtech Stocks that have appear to be trending by receiving buy ratings and showing positive investor sentiment, as well as news headlines. With that said, our editors are adding them to our watchlist to see if the momentum continues. --------------------------------------------------------------- Sponsor [Americans Now Favor Gold Over Stocks as an Investment Vehicle]( [See why investors are so impressed by this overlooked gold investment strategy.]( --------------------------------------------------------------- [Tenet Healthcare Corporation, THC]( Summary: Tenet Healthcare Corp. is an investor-owned health care services company, which owns and operates general hospitals and related health care facilities for urban and rural communities in numerous states, and has offices in California and Florida. The company has investments in other health care companies and is one of the largest investor-owned health care delivery systems in the United States. Tenet Healthcare and its subsidiaries provide healthcare services primarily through general hospitals and related healthcare facilities. Its hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies; intensive care, critical and coronary care units; physical therapy along with orthopedic, oncology, and outpatient services. The related health care facilities include rehabilitation hospitals, specialty hospitals and long-term care facilities. David S analyst at Truist Financial reiterates coverage on [Tenet Healthcare Corporation (THC)](in the Health sector with a Buy rating and has set a price target of $105. [TipRanks.com]( reports that [Tenet Healthcare Corporation](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $103.60. In addition, TradingView issued a buy rating for [THC]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on THC, please click here >>]( --------------------------------------------------------------- [Illumina, Inc., ILMN]( Summary: Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts. Catherine Ramsey analyst at Robert W. Baird reiterates coverage on [Illumina, Inc. (ILMN)](in the Health sector with a Hold rating and has set a price target of $146. [TipRanks.com]( reports that [Illumina, Inc.](currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $140.20. In addition, TradingView issued a sell rating for [ILMN]( over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on ILMN, please click here >>]( --------------------------------------------------------------- Sponsor [Gold Could Be Heading for Record Highs - But How to Play It?]( to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. [See this little-known way to play in the rising gold market.]( --------------------------------------------------------------- [Zimmer Biomet Holdings, Inc., ZBH]( Summary: Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Richard Newitter analyst at Truist Financial reiterates coverage on [Zimmer Biomet Holdings, Inc. (ZBH)](in the Health sector with a Hold rating and has set a price target of $135. [TipRanks.com]( reports that [Zimmer Biomet Holdings, Inc.](currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $132.80. In addition, TradingView issued a Neutral rating for [ZBH]( over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on ZBH, please click here >>]( --------------------------------------------------------------- [McKesson Corporation, MCK]( Summary: McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions. Ann Hynes analyst at Mizuho Securities reiterates coverage on [McKesson Corporation (MCK)](in the Health sector with a Hold rating and has set a price target of $505. [TipRanks.com]( reports that [McKesson Corporation](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $557.20. In addition, TradingView issued a Strong buy rating for [MCK]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on MCK, please click here >>]( --------------------------------------------------------------- Sponsor [1947 → Control of Your Money in 2024???]( 1947, Harry Truman signed a little-known law. It established a secret, dangerous “4th branch" of government targeting US citizens like you and me. Thanks to Truman's law, your constitutional rights are now in clear and present danger this year. Just 4 months before the 2024 elections… A new mass citizen surveillance program will be rolled out. It's called Rule 613. And it will spy on 200 million Americans. [To protect your freedom, privacy, and money click right here.]( --------------------------------------------------------------- --------------------------------------------------------------- Sponsor [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [TipRanks.com]( tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [HealthTechMovers.com]( --------------------------------------------------------------- Sponsor [The Strategic Gold Play You Haven't Heard About]( recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. [Get the full story on this overlooked gold investment strategy here.]( --------------------------------------------------------------- ConsumerStockMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software